TECENTRIQ® atezolizumab

Roche

DOSING GUIDE

This guide refers to dosing of patients prescribed TECENTRIQ as per the EU Summary of Product Characteristics (SmPC). Treatment with TECENTRIQ must be initiated and supervised by physicians experienced in the treatment of cancer. For TECENTRIQ approved indications and full administration support see the SmPC.

STANDARD TECENTRIQ ADMINISTRATION

- TECENTRIQ is for IV use (**not** IV push or bolus).
- Initial TECENTRIQ dose must be administered over 60 mins. If well tolerated, subsequent infusions may be administered over 30 mins.
- Dose reductions of TECENTRIQ are not recommended.
- If a planned dose of TECENTRIQ is missed, it should be administered as soon as possible.
- TECENTRIQ treatment is recommended until loss of clinical benefit or unmanageable toxicity.
- For pre-treatment care, pre-medication, lab tests, recording of vital signs and follow up, refer to local guidelines and individual SmPCs.

IMMUNE-RELATED ADVERSE REACTIONS



INFUSION-RELATED REACTIONS

The rate of infusion should be reduced or treatment should be interrupted in patients with Grade 1 or 2 infusion-related reactions. TECENTRIQ should be permanently discontinued in patients with Grade 3 or 4 infusion-related reactions.

Published by F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland | © December 2020
www.roche.com

M-XX-00003869

TNBC 1L

TECENTRIQ +NAB-PACLITAXEL

Treatment recommended until disease progression or unmanageable toxicity.

Three flexible & convenient fixed dosing options.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

TECENTRIQ	DAYS 1, 8, & 15
	NAB-PACLITAXEL 100 mg/m²
30 minutes 60 min for 1st infusion	30 minutes

SCLC

TECENTRIQ +CARBOPLATIN +ETOPOSIDE

Treatment recommended until disease progression or unmanageable toxicity.

Three flexible & convenient fixed dosing options.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

INDUCTION | Q3W			MAINTENANCE | Q2W, Q3W or Q4W
TECENTRIQ	CARBOPLATIN AUC 5 mg/ml/min[a]	ETOPOSIDE 100 mg/m²	TECENTRIQ
30 minutes 60 min for 1st infusion	30-60 minutes	60 minutes same dose administered on Days 2 and 3 as well	30 minutes

[a]Dose may vary as per local protocol and/or renal function

NSCLC 1L

TECENTRIQ + AVASTIN + PACLITAXEL + CARBOPLATIN

Three flexible & convenient fixed dosing options.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

INDUCTION | Q3W 4 TO 6 CYCLES				MAINTENANCE | Q3W	
TECENTRIQ	AVASTIN 15 mg/kg	PACLITAXEL 200 mg/m²	CARBOPLATIN AUC 6 mg/ml/min[a]	TECENTRIQ	AVASTIN 15 mg/kg
30 minutes 60 min for 1st infusion	30 minutes 90 min for 1st infusion 60 min for 2nd infusion	180 minutes	15 - 30 minutes [a]Dose may vary as per local protocol and/or renal function	30 minutes	30 minutes

NSCLC 1L

TECENTRIQ +NAB-PACLITAXEL +CARBOPLATIN

Treatment recommended until disease progression or unmanageable toxicity.

Three flexible & convenient fixed dosing options.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

INDUCTION | Q3W 4 TO 6 CYCLES			MAINTENANCE | Q2W, Q3W or Q4W
Day 1 TECENTRIQ	DAYS 1, 8 & 15 NAB-PACLITAXEL 100 mg/m²	Day 1 CARBOPLATIN AUC 6 mg/ml/min[a]	TECENTRIQ
30 minutes 60 min for 1st infusion	30 minutes	15 - 30 minutes [a]Dose may vary as per local protocol and/or renal function	30 minutes

NSCLC 2L

TECENTRIQ

Three flexible & convenient fixed dosing options.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

DOSING OPTIONS | Q2W, Q3W or Q4W

TECENTRIQ: 30 minutes 60 min for 1st infusion

Until loss of clinical benefit or unmanageable toxicity.

UC

TECENTRIQ

Three flexible & convenient fixed dosing options.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

DOSING OPTIONS | Q2W, Q3W or Q4W

TECENTRIQ: 30 minutes 60 min for 1st infusion

Until loss of clinical benefit or unmanageable toxicity.

HCC

TECENTRIQ + AVASTIN

Q3W is the recommended dosing frequency for TECENTRIQ combination therapies.

- 4-week interval 1680 mg IV (2x 840 mg IV)
- 3-week interval 1200 mg IV
- 2-week interval 840 mg IV

TECENTRIQ

DOSING OPTIONS | Q3W

TECENTRIQ	AVASTIN 15 mg/kg
30 minutes 60 min for 1st infusion	30 minutes 90 min for 1st infusion 60 min for 2nd infusion

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

TECENTRIQ SC approved in the EU for all indications of intravenous TECENTRIQ[1]*

SCHEDULING	PREPARATION	ADMINISTRATION
Every 3 weeks	Fixed dose 1875 mg SC (1 x 1875 mg vial)	Approximately 7 minutes for the first and subsequent injections

* including certain types of lung, liver, bladder and breast cancer. Please refer to the TECENTRIQ SmPC for further information